Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript

Sergio Traversa: How many doses? No, we haven’t finalized the exact dose regimen. We’ll discuss in the IND. But what I can share with you is what will be the dose limiting toxicity. And it is not real toxicity because we know that psilocybin is well tolerated from the literature and the history and from other programs that are ongoing that are using 20 mg, 25 mg in a single dose. And we will use one-tenth of that. So it’s a fair assumption that the dose we’ll be using will not be toxic or not well tolerated in general terms. But the dose limiting toxicity that we are trying to determine is when you start to have psycho symptoms, if I put it in this way, when you start to feel that the drug is affecting your psych. So, we are developing a low dose extended release that is non-psychedelic. So the dose limiting toxicity will be the psychedelic effect. We don’t know exactly what the dose is, but we assume that it will be below 3 mg, 4 mg daily.

Operator: Thank you. There are no further questions at this time. Please proceed.

Sergio Traversa: Well, thank you. Look, in summary, we remain confident that we do have an approvable drug in REL-1017, and we are excited about the potential of the novel psilocybin in derivative problems. We look forward to reporting the progress with our pipeline in the months ahead. And I do remain grateful to the Relmada team for their continued hard work and dedication to executing on our mission. I would like to extend my sincere thanks to the patients and clinical partners involved in the REL-1017 trials for their participation in the advancement of this promising investigational medicine to development. Thanks a lot to everyone and we’ll reconnect soon.

Operator: Thank you. Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.